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Abstract
Supplement manufacturers are widely unregulated and are only held accountable for
products if their supplement is shown to cause harm. To take advantage, some
manufacturers use false or sensationalized claims that have little or no scientific backing.
Due to the lack of testing for many supplements, this study will seek to determine
multiple effects of the weight loss supplement, Shred Matrix.
PURPOSE: The purpose of this study was to 1) examine the acute effects of the weight
loss aid, Shred Matrix, on hemodynamic responses, substrate utilization, endurance,
arterial compliance, and body water distribution; 2) To investigate the differences
between athletes and non-athletes on the previously stated measures.
METHODS: 31 subjects underwent a randomized, double-blind, crossover design study
and were given a placebo or Shred Matrix on two separate days. Baseline measures of all
variables were assessed prior to exercise. During exercise, each subject ran on a treadmill
at 80% VO2 Max until volitional fatigue. While running, HR, VO2, and respiratory
exchange ratio were continuously monitored. Immediately post-exercise, arterial
elasticity was measured at 0, 10, 20, and 40 minutes. Body fluid analyses were performed
at 5 and 30 minutes post-exercise. PWV was measured at 5, 15, 25, and 35 minutes postexercise.
RESULTS: Significant condition differences existed for ECF in non-athlete males
(p=.023). Carotid to radial PWV was significant (p=.01). There was a significant
condition*time interaction with Shred Matrix having a higher PWV for the carotid to
femoral segment (p=.003) and the femoral to distal segment (p=.018). LAE was
significantly lower for Shred Matrix (p=.003). SBP was conditionally higher (p=.001), as
was DBP (p=.003), MAP (p=.001), and PP (p=.035). There were significant
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condition*time interactions for PR (p=.001) and SV (p=.016). VR was conditionally
significant (p=.05). RER while running was significantly higher (p=.034) with Shred
Matrix. Only female non-athletes ran longer on Shred Matrix (p=.033).
CONCLUSION: Shred Matrix caused multiple negative effects in hemodynamics and
arterial compliance. Consumers should educate themselves before purchasing
supplements and visit with a physician to determine any preexisting conditions that might
be cause for concern.
KEYWORDS: Shred Matrix, supplement, weight- loss
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CHAPTER I
INTRODUCTION

By law, dietary supplement manufacturers are not required to receive Food and
Drug Administration (FDA) approval before producing or selling a dietary product. This
means that manufacturers are able to introduce substances into their products without
labeling or including dosage sizes. Companies are also able to invent false or
sensationalized claims as long as their disclaimer reads, “these statements have not been
evaluated by the FDA.” Their only obligation is to register the product and report
instances of adverse effects. The policy is reactionary; action against a harmful
supplement is not taken unless catastrophic events happen to draw attention to a harmful
product or ingredient (FDA, 2015).
A well-known incident of an ingredient in supplements being harmful is
ephedrine in the early 2000s. A report published by the FDA in 2003 performed a metaanalysis over ephedrine and ephedrine-containing products. Their results found a modest
increase in fat loss, but a two to three fold increase for the risk of nausea, vomiting,
psychiatric symptoms, autonomic hyperactivity, and palpitations. There were also reports
of a total of five deaths from the ingredient (Shekelle, Morton, Maglione, et al. 2003).
Consequently, the FDA banned ephedrine four months later.
With over 1500 establishments that manufacture dietary supplements (Karns,
2000) there is a need for products and ingredients to be tested to substantiate claims of
efficacy. Companies that possess research backing their products will have more
credibility for consumers. They will also provide evidence for new findings that may
allow ingredients to treat diseases where medication is ineffective or unwanted.

Study Purpose
The purpose of this study was to 1) examine the acute effects of the weight loss
aid, Shred Matrix, on hemodynamic responses (i.e., heart rate, blood pressure, stroke
volume, and ejection time), substrate utilization, endurance, arterial compliance, pulse
wave velocity, and body water distribution; 2) To investigate the differences between
athletes and non-athletes on the previously stated measures.
Research Questions
1.

Was there a significant increase in fat metabolism when the weight loss aid,
Shred Matrix, if consumed prior to exercise?

2.

What were the changes in exercise HR, exercise diastolic and systolic BP?

3.

Was there a significant effect on stroke volume?

4.

Was there a significant effect on ejection time?

5.

Was there an increase in exercise endurance?

6.

Was there a change in arterial compliance?

7.

Was there a significant effect on pulse wave velocity?

8.

Was there a change in intracellular and/or extracellular body water?

Hypotheses
1.

There was a greater amount of fat metabolism with Shred matrix during
exercise.

2.

Shred Matrix resulted in lower increases in HR, diastolic and systolic blood
pressures at different time points compared to placebo.

3.

There was a significant increase in stroke volume.

4.

There was an increase in cardiac ejection time.

5.

Shred Matrix resulted in increased time to exhaustion.
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6.

There was an increase in large and small arterial elasticity.

7.

There was a decrease in pulse wave velocity.

8.

There was an increase in extracellular water.

Significance of the Study
The Dietary Supplement Health and Education Act of 1994 (DSHEA) defines
dietary supplements as “products that, among other things, are intended for ingestion to
supplement the diet, labeled as dietary supplements, and not represented as conventional
foods or as a sole items of a meal or diet” (Dietary Supplement Health and Education Act
of 1994). Under the DSHEA, supplements are generally considered as being safe and the
Food and Drug Administration (FDA) has no authority to regulate the market unless a
product has been shown to be dangerous to the public. Supplement manufacturers are not
required to provide evidence for claims so long as there is no claim that a product can
“treat, prevent, or cure” a disease (GAO-10-662T). With such a large amount of freedom
given to manufacturers, there is a need for more research into supplementation to provide
accountability for businesses creating these supplements and to educate consumers on the
effectiveness of their purchases.
Shred Matrix claims to be a weight loss supplement and mood enhancer designed
specifically for athletes. There are several active ingredients contained within the
supplement that have been previously studied and shown to support those claims. It is
important that this study observe the effects of Shred Matrix on heart rate, blood pressure,
substrate utilization, endurance, arterial compliance, stroke volume, ejection time, and
body water distribution to determine if their claims are substantiated and to add to the
body of knowledge concerning the ingredients listed.
3

Delimitations
1. Since arterial elasticity is affected by age, only males and females between the
ages of 18-40 were allowed to participate in the study.
2. Individuals suffering from diseases that prevent subjection to maximal testing
were excluded. These included hypertension, metabolic, and cardiovascular
diseases.
3. Individuals suffering from disabilities that prevented maximal testing were
excluded. These included joint injuries or chronic pain.
4. Individuals who were currently or took ergogenic aids other than caffeine within
the previously 30 days before testing were excluded.
5. Subjects were required to be adequately hydrated before testing.
Limitations
1. The study might not be representative of the population due to all participants
being volunteers and not being randomly sampled.
2. Health history and medical information were gathered through self-report.
3. Participants were asked to refrain from ingesting caffeine, alcohol, or engaging in
intense exercise for at least 24 hours before testing, but diet and activity were not
monitored.
Assumptions
1. Subjects performed each maximal test and volitional fatigue test to the best of
their ability.
2. Subjects arrived fasted and adequately rested on testing days.
3. Accurate health history and medical information were provided.
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4. The equipment used was reliable and provided accurate information for each
testing session.
Operational Definitions
Athlete: Having a VO 2MAX (ml/kg/min) deemed “excellent” according to age for females
and males as determined by either the greatest measure gathered by metabolic cart or
time to exhaustion during the Bruce Protocol (Nunes, 2005).
Non-athlete: Having a VO 2MAX (ml/kg/min) deemed less than “excellent” according to
age for females and males as determined by either the greatest measure gathered by
metabolic cart or time to exhaustion during the Bruce Protocol (Nunes, 2005).
Hydration: Hydration status was deemed adequate when urine specific gravity measured
1.010 and lower as determined by a clinical urine refractometer (Case et al., 2000).
PAR-Q: PAR-Q (Physical activity readiness questionnaire) is a screening tool that is
designed to determine whether a subject may perform the exercise in a safe and risk free
manner.
Ergogenic Aid: are any external influences that can be determined to enhance
performance in high- intensity exercises.
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CHAPTER II
REVIEW OF THE LITERATURE

The purpose of this study was to 1) examine the acute effects of the weight loss
aid, Shred Matrix, on hemodynamic responses (heart rate, blood pressure, stroke volume,
ejection time) substrate utilization, endurance, arterial compliance, pulse wave velocity
and body water distribution; 2) To investigate the differences between athletes and nonathletes on the previously stated measures.
Unlike weight loss supplements tailored to be taken by a sedentary and obese
population, Shred Matrix claims to be “a weight loss system designed for athletes.”
According to the manufacturers this is achieved through an eight stage approach
consisting of: Stages 1 and 2 increase energy and ramp up metabolism. Stages 3 and 4
crush hunger. Stage 5 balances mood and enhances well-being. Stage 6 maintains sharp
mental focus without jitters. Stage 7 eliminates excess water. Stage 8 contains a
trademarked Sugar Stop

T M and enzyme

aid matrix.

Ingredients Affecting Body Fluid
Weight loss is also obtained from this supplement through loss of water. There are
two ingredients that are listed in Shred Matrix that have been associated with water loss,
uva ursi leaf and dandelion root. The American Medical Association classifies both
dandelion root and uva ursi leaf as diuretics to increase body fluid loss (Miller, 1998).
Uva Ursi Leaf
Uva ursi is most commonly used as a natural remedy to treat urinary tract
infections. However on review cited a study done in animals where uva ursi acted as a

diuretic without impacting potassium or sodium levels (Head, 2008). No human studies
for uva ursi’s effects on body fluid were discovered while reviewing literature.
Dandelion Root
A study was designed by Clare et al. (2009) to determine the diuretic effects of
dandelion root on 28 females aged 18-65. The trials took place over a 4 day period where
subjects monitored their fluid intake and urine excretion with or without the supplement.
The results showed a significant increase in urination following dosages of dandelion root
with a decrease near baseline levels the day following supplementation. The authors
revealed that the test was not blinded, there were a small number of subjects, fluid input
was self-monitored, there was no correction for water from food, and limited baseline
values for urine output. Despite the limitations, the authors felt the results warranted
further investigation into the natural diuretic, dandelion root (Clare, Conroy, & Spelman,
2009).
Ingredients Affecting Hemodynamics
Shred Matrix contains ingredients that both positively and negatively affect
hemodynamics. This may lead to either higher central pressures, lower, or they may be
cancelled out and remain unchanged.
Garlic
Garlic has been shown to lower blood pressure in hypertensive subjects. Seventynine subjects took part in a 12-week double-blind, randomized, placebo-controlled
parallel trial. Subjects were split between four groups, 3 varying garlic groups and one
placebo group. The results of the study showed that garlic supplementation was superior
to placebo in lowering systolic blood pressure in subjects with hypertension in the higher
dosage groups (Ried, Frank, & Stocks, 2013).
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In trained cyclists, there was no significant difference found in blood pressure
under hypoxic conditions. Nine healthy subjects underwent 7 days of garlic
supplementation, a 7 day washout period, and then another 7 day supplementation period
with maximal testing pre and after each supplementation period. All exercise testing was
done on cycle ergometers. Treatments were applied in a randomized, single-blind,
crossover fashion. The results of the study concluded that under hypoxic conditions in
trained cyclists, there was no significant decrease in SBP or DBP (Morris, Beloni, &
Wheeler, 2013).
Caffeine
Caffeine is one of the primary ingredients listed in Shred Matrix. In 2004, the
World Anti-Doping Agency removed caffeine from its list of banned substances, and
more than 60 peer-reviewed articles have been published on caffeine and its role in sport
performance enhancement (Desbrow & Leveritt, 2007). Caffeine has been shown to
increase systolic and diastolic blood pressure through increases in peripheral vascular
resistance at rest. One study performed on young, healthy, normotensive men volunteered
to take part in a double-blind cross-over study. Subjects came in on two different days
separated by at least 48 hours. They were randomly assigned either 3.3 mg/kg caffeine or
a placebo and rested for 40 minutes. Afterwards, subjects performed multiple 3 minute
cycling stages of increasing intensity. After one hour of rest, subjects performed maximal
cycling testing. Results showed increases in systolic and diastolic blood pressure and also
increases in peripheral vascular resistance. The authors speculate that caffeine inhibited
the adenosine receptor responsible for vasodilation. The resultant vasoconstriction caused
increases in central pressure (Sung, Lovallo, Pincomb, & Wilson, 1990).
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Another study observed the hemodynamic responses to caffeine at rest. Fifteen
males, aged 20-35 years were blinded and received either caffeinated or a placebo
beverage. Every ten minutes measures were taken, up to 40 minutes post ingestion, while
subjects remained in a semi-recumbent position. Results showed significant increases in
systolic and diastolic pressure and increased systemic vascular resistance (Pincomb et al.,
1985).
Ingredients Affecting Arterial Elasticity
Turmeric
Turmeric is derived from the plant Curcuma longa and has many potential health
benefits, including potential increases in arterial elasticity. One of the few studies
observing turmeric’s effects on arterial elasticity measured differences between 51
postmenopausal women separated into four groups. The four groups consisted of two
exercise groups, one of which also received turmeric, and two non-exercise groups, one
of which received turmeric. The four groups ingested 150mg of turmeric or a placebo
each day for 8 weeks and the exercise groups were given an aerobic workout plan. The
results of the experiment showed positive increases in carotid arterial elasticity for all
groups except the non-exercise placebo group. Turmeric only supplementation showed
positive effects similar to the exercise only group, and combined exercise and turmeric
demonstrated the greatest increases in carotid arterial compliance (Akazawa et al., 2013).
Caffeine
Caffeine’s effects on hemodynamic may also relate to changes in arterial
elasticity. Seven healthy subjects ingested either 250mg of caffeine through coffee or
drank decaffeinated coffee on two different days divided by at least one week. After
ingestion, subjects were observed for 90 minutes in the supine position with carotid to
9

femoral pulse wave velocity measurements taken every 30 minutes. Results showed acute
increases in vascular stiffness, even after adjustment for blood pressures (Mahmud &
Feely, 2001).
Ingredients Affecting Endurance
There is a relationship between endurance activities and fat oxidation. The ability
to perform for longer periods of time at a given intensity means that more fat is being
burned to meet energy demands. As a weight loss supplement, Shred Matrix contains
ingredients that have been shown to increase endurance, and thus burn more fat and
lower body mass. The ability to utilize more fat comes in part from a sparing of glucose.
A negative fat balance can also be had by maintaining steady insulin levels after ingestion
of carbohydrates to avoid storing glucose in adipose tissue. Utilizing both approaches
from the ingredients in the product allow fat to be utilized more as an energy source and
have less fat stored.
Caffeine
Caffeine has previously been shown to improve performance by promoting
plasma free fatty acid (FFA) mobilization and sparing muscle glycogen (Spriet et al.,
1992), however later studies credit better performance to increases in central nervous
system (CNS) stimulation and muscle recruitment (Cox et al., 2002)
Aside from reported physiological effects of caffeine, there may be a
psychological component to increasing endurance performance (Marcora, Staiano, &
Manning, 2009). Adenosine, a neurotransmitter, is responsible for inhibiting excitatory
neurotransmitters leading to reduced arousal, increased sleep, and feelings of fatigue.
During the day or throughout exercise, adenosine levels progressively increase until
fatigue or exhaustion sets in. Researchers speculate that adenosine may be partially
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responsible for fatigue in endurance exercise (Davis et al., 2003). Caffeine directly
inhibits adenosine receptors and may explain in part why ingestion of caffeine leads to
increases in exercise duration (Cox et al., 2002). Research on rats has already shown that
low doses of caffeine inhibit adenosine and was responsible for longer exercise durations
until exhaustion (Davis et al., 2003).
Eleutherococcus senticosus
Eleutherococcus senticosus (ES) is a shrub native to forests in Russia, China,
Japan, and Korea. The active ingredients in ES are known as eleutherosides. The plants
and its derivatives are normally safe, but diarrhea and insomnia have been reported as
possible side effects(Kuo, 2010).
Nice recreationally trained college males were given either 800mg/d of ES or a
placebo during an 8 week randomized, double-blind, placebo-controlled with a crossover
design study to determine its effects on endurance capacity, cardiovascular functions, and
metabolism. Pre and post-test values were measured on a bicycle ergometer at 75% VO 2
peak. The results of the study showed a 12% increase in VO2 peak, endurance time
increased 23%, and max HR increased 4%. The authors attributed the positive endurance
results to a shift of burning more fatty acids as a fuel instead of glucose (Kuo, 2010).
Biotin and Chromium
The essential trace mineral, chromium, was identified over 40 years ago as being
a part of lipid and carbohydrate metabolism. Since then, there have been multiple studies,
both animal and human, that demonstrate the efficacy of chromium supplementation for
type 2 diabetes (Albarracin, Fuqua, Evans, & Goldfine, 2008). Biotin is part of the B
vitamin group, specifically B7 . It is water soluble and plays a role in carbohydrate and
lipid metabolism. Biotin affects metabolism by stimulating genes that affect glycaemic
11

control in the pancreas and liver. It also suppresses phosphoenolpyruvate carboxykinase,
which is one of the enzymes involved in gluconeogenesis. This suppression will inhibit
new glucose molecule formation, thus maintaining lower blood glucose levels
(Albarracin et al., 2008).
Four hundred and forty-seven subjects with type 2 diabetes and HbA1c ≥7 were
divided into and experiment or control group for 90 days. HbA1c refers to the amount of
hemoglobin that is combined with blood glucose to become glycated. Each group
received either biotin with chromium picolinate or a placebo. The results of the study
showed a significant improvement in fasting blood glucose levels and HbA1c, especially
when HbA1c levels pretest were ≥10 (Albarracin et al., 2008).
Biotin has been studied extensively in diabetic animals. “In genetically diabetic
KK mice and in Otsuka Long Evans Tokushima Fatty (OLETF) rats, biotin treatment
lowered postprandial glucose concentration and improved tolerance to glucose.” This
means that biotin supplementation may lower glucose absorption, thus lowering insulin
response and preventing excess carbohydrate from being stored as fat (Fernandez-Mejia,
2005).
Capsaicin
Capsaicin is the component generally found in cayenne pepper and is responsible
for its hot and spicy flavor. Its use has been studied with results indicating that both
energy expenditure and fat oxidation increased (Ahuja, Robertson, Geraghty, & Ball,
2006). Other studies suggest that capsaicin may be used to lower blood glucose by
increasing insulin levels in healthy human subjects (Dömötör, Szolcsányi, & Mózsik,
2006). At this time there were no studies found investigating the effects of capsaicin on
diabetic humans.
12

Eight male mice, aged one week, were fed a high fat diet for a total of 20 weeks.
They were divided at week 10 into an experiment and control group. The experimental
group was administered capsaicin with their high fat diet while the control continued to
receive only the high fat diet. The group receiving capsaicin had significantly lower
levels of insulin and glucose 60 minutes after ingesting glucose. The results showed that
capsaicin protected against glucose intolerance in obese mice (Kang et al., 2010).
Twelve healthy volunteers participated in a crossover study designed to test the
effects of capsaicin on blood glucose levels. Baseline levels of insulin and fasted blood
glucose were taken. Subjects were then administered 75g of glucose followed by 5g of
either capsaicin or a placebo. With capsaicin ingestion, lower blood glucose levels were
observed at 30 and 45 minutes post ingestion. Insulin levels were higher than the placebo
group during the time period. Afterwards, insulin levels dropped back to basal levels for
the experimental group while insulin levels continuously decreased below basal levels in
the control (Weerapan Khovidhunkit, 2009).
Dömötör et al. studied fourteen healthy human subjects. Each subject was selfcontrolled and was administered 75mg of glucose orally either with or without capsaicin.
Blood glucose, insulin, and glucagon levels were measured every 15 minutes for 4 hours.
The study found that capsaicin was responsible for an initial increase in insulin levels
which demonstrated an increase in absorption. Glucagon levels also increased
independently from insulin. The authors speculated that capsaicin was responsible for
stimulating afferent nerves responsible for glucagon synthesis (Dömötör et al., 2006).
Gymnema Sylvestre
Gymnema sylvestre is a plant that acts to improve blood glucose levels in two
ways. First, it acts to stimulate insulin secretion (Al-Romaiyan et al., 2010). Second, it
13

suppresses glucose absorption in the small intestine. This will cause a slower rise in
blood glucose and can become easier to control (Kurian, Manjusha, Nair, Varghese, &
Padikkala, 2014).
Banaba Extract
Banaba is touted as being an insulin mimetic, meaning it acts in the way that
insulin does to decrease blood glucose. It has primarily been used in folk medicine in
Southeast Asia to treat diabetes. According to some studies, it may also be beneficial in
controlling hyperlipidemia and act as an anti-inflammatory (Miura, Takagi, & Ishida,
2012).
Subjects with mild diabetes were recruited to perform a randomized, double-blind
study for 6 months to determine the effectiveness of Banaba extract and other
components on blood glucose. The results showed no significant difference in blood
glucose homeostasis. However, the researchers did find that there was a decrease in
biomarkers that signal inflammation. The author speculated there may not have been a
significant difference in blood glucose levels due to the multiple herbs in their cocktail
interfering with each other (Kim et al., 2012).
Six-week-old mice were fed a high fat diet for 9 weeks, with the experimental
mice receiving corosolic acid, derived from Banaba leaves, and the control receiving only
the high fat diet. Mice receiving the corosolic acid had 10% less body weight than the
control. Plasma glucose was 23% lower for the experimental group, and insulin was also
lower by 41%. This suggested that the corosolic acid mice had higher insulin sensitivity.
The lower weight was explained through activation of the peroxisome proliferatoractivated receptor (PPAR), which is responsible for gene expression that affects lipid
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metabolism. PPAR activation from corosolic acid would lead to higher level of fat
oxidation (Yamada et al., 2008).
Twelve subject, 7 males and 5 females, were recruited to test the efficacy of
Banaba extract on blood glucose. Fasting blood glucose was measured, followed by a
540kcal meal consisting of 100% starch. Plasma glucose levels were then measured at 30,
60, and 120 minutes after ingestion. For the next two weeks, Banaba extract was
administered orally every morning. No changes in plasma glucose were reported,
however there was an improvement in BMI (Tsuchibe, Kataumi, Mori, & Mori, 2006).
Turmeric
Along with increasing arterial elasticity mentioned earlier, turmeric has also been
found to possess antioxidant and antimutagenic capabilities, while also inhibiting
glucosidase enzymes (Gupta et al., 2013). Alpha and beta glucosidase are responsible for
breaking down compound carbohydrates into simpler sugars that will lead to high blood
glucose levels. Inhibiting these enzymes will cause blood glucose to rise at a slower rate
and be easier to manage (Lekshmi, Arimboor, Indulekha, & Nirmala Menon, 2012).
Type 2 diabetic subjects participated in a randomized, double-blind, and placebo
controlled study to determine the efficacy of turmeric on proteinuria, serum transforming
growth factor, tumor necrosis factor, and urinary levels of interleukin-8. The primary
results of the study are beyond the scope of this review, but the researchers also observed
fasted plasma glucose and 2 hours postprandial blood glucose. They found no significant
difference for either category (Khajehdehi et al., 2011).
Genetically diabetic mice were divided into 3 groups of 5 mice each by body
weight and blood glucose. The control was fed the basal diet only, while the two
experimental groups were fed turmeric either .2 or 1g/100g of the diet. After 4 weeks
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blood samples were obtained. The control group saw a significant rise in blood glucose
after 4 weeks of feeding while both experimental groups stayed the same. This led the
authors to speculate that turmeric supplementation may lead to preventing type 2 diabetes
(Kuroda et al., 2005).
Fourteen healthy subjects in a crossover trial ingested 75g of glucose together
with either 6g of Curcumin longa or a placebo. Blood samples were taken using finger
prick to measure glucose and insulin levels at 15, 30, 45, 60, 90, and 120 minutes. The
results of the study concluded that there was no significant difference in plasma glucose
from an acute dose of Curcumin longa. However, the study show significance in insulin
levels after 30 minutes postprandial up to 1 hour. The author speculated that Curcumin
longa may stimulate beta cells in the pancreas to release more insulin (Wickenberg,
Ingemansson, & Hlebowicz, 2010).
Conclusion
This review brings to light some potential conflicting ingredients in Shred matrix.
Caffeine can cause increases in central pressures and arterial stiffness, and also improve
aerobic endurance (Mahmud & Feely, 2001; Pincomb et al., 1985; Sung et al., 1990).
Garlic has been shown to decrease blood pressure through vasodilation, which may or
may not offset caffeine’s vasoconstriction (Ried et al., 2013). Turmeric’s positive effects
on arterial elasticity may also be negated by stiffening caused by caffeine in an acute
dosage of Shred Matrix.
Simply because an ingredient is listed on the label of a product, it does not mean
that the ingredient will cause any affect. Also, the proprietary blend posted on some
supplement labels means that manufacturers do not have to disclose the amount of
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ingredient contained within the product. Studies such as this will help determine various
effects of supplements and provide speculation as to the causes observed.
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CHAPTER III
METHODS

The purpose of this study was to 1) examine the acute effects of the weight loss
aid, Shred Matrix, on hemodynamic responses (i.e., heart rate, blood pressure, stroke
volume, and ejection time), substrate utilization, endurance, arterial compliance, pulse
wave velocity, and body water distribution; 2) To investigate the differences between
athletes and non-athletes on the previously stated measures.
Subjects
Fifteen male and sixteen female participants between the ages of 18 and 40 years
were recruited for this study. The length of testing for each subject was one 60 minute
introduction session and two experimental sessions that lasted approximately 150 minutes
each, for a total of 6 hours.
Inclusion Criteria
1. Subjects must have been between 18-40 years of age.
2. Subjects must not have had hypertension, cardiovascular disease, any metabolic
disease, chronic pain, or joint problems.
3. Subjects must not have been taking any other ergogenic aid, with the exception of
caffeine, for the previous 30 days.
Exclusion Criteria
1. Subjects that were taking medication for hypertension.
2. Subjects that were taking medication for cardiovascular disease.

3. Subjects that were suffering from chronic pain.
4. Subjects were suffering from joint injuries in the lower extremities.
5. Subjects were currently or within the previous 30 days had consumed another
ergogenic aid other than caffeine.
Recruitment
Subjects were recruited from The University of Texas at Brownsville, Texas
Southmost College and the surrounding community by fliers and word of mouth.
Participation in this study was voluntary and subjects were allowed to withdraw at any
time.
Experimental Protocol
The first day included filling out paperwork and familiarization of testing
protocols. Paperwork consisted of signing an informed consent form, completing the
physical activity readiness questionnaire (PAR-Q), and a health status questionnaire.
After completing paperwork, anthropometric measures that included height, weight,
resting heart rate (HR), and resting blood pressure (BP) were assessed and recorded.
Subjects then performed the Bruce Protocol. Testing consisted of running on a treadmill,
with increasing speeds and incline, until exhaustion. Subjects were fitted with a mask for
the metabolic cart, and gas exchange, perceived exertion, and heart rate were monitored
continuously by the metabolic cart while performing VO2 Max testing.
For the two experimental protocols, participants were required to be fasted for at
least 8 hours prior to testing. Sessions were randomized and either a placebo or Shred
Matrix (MusclePharm Corp., Denver, CO, USA) were given on two separate days with at
least 48 hours between each session. Upon arriving, subjects were required to give a urine
sample measured by Clinical Urine Refractometer 300005 (SPER Scientific, Scottsdale,
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AZ, USA) to determine hydration levels. If inadequately hydrated, subjects were
instructed to drink water to reach proper hydration. Urine samples were continuously
collected every 20 minutes until subjects were deemed hydrated according to preset
standards. The subjects’ HR and BP were assessed prior to the start of exercise.
Intracellular and extracellular body fluids were analyzed via Hydra ECF/ICF Model 4200
Bio-Impedance Spectrum Analyzer (Xitron Technologies, Inc., San Diego, CA, USA).
Baseline arterial compliance, left ventricular ejection time and fraction were recorded via
the HDI/PulseWave CR-2000TM Research Cardio Vascular Profiling System
(Hypertension Diagnostic, Inc., Eagan, Minnesota, USA). Baseline pulse wave velocity
was also recorded prior to exercise via SphygmoCor® CPV Pulse Wave Analyzer (AtCor
Medical, Itasca, IL, USA). During exercise, each subject exercised until volitional fatigue
on a treadmill at 80% predicted VO2 Max. Immediately post exercise, arterial elasticity
was measured at 0, 10, 20, and 40 minutes. Body fluid analyses were performed at 5 and
30 minutes post-exercise. Pulse wave velocity was measured at 5, 15, 25, and 35 minutes
post-exercise. During testing, heart rate, VO2, and RER was continuously monitored.
Calibration of all the equipment was performed regularly according to instructions
provided by the manufacturers.
VO2MAX
Participants were required to wear a breathing mask that was connected to the
MOXUS Modular VO2 System (AEI Technologies, Inc., Pittsburgh, PA, USA) through a
mask and breathing tubes. Inspired oxygen and expired carbon dioxide was collected by
the metabolic cart computer and analysis and calculations of energy expenditure and
oxygen consumption was recorded by the software. Heart rate was assessed by wearing a
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Polar Heart Rate Monitor FT7 Series (Polar Electro Inc., Lake Success, NY, USA) and
recorded in the data collection sheet.
Bruce Protocol
The Bruce Protocol consisted of multiple stages of increasing speeds and inclines
until maximal exertion was reached. The metabolic cart recorded the exchange of gases
inhaled and expired to indirectly determine how much oxygen was consumed.

Table 1. Bruce Protocol
Stage Minutes % grade km/h MPH
1

3

10

2.7

1.7

2

6

12

4.0

2.5

3

9

14

5.4

3.4

4

12

16

6.7

4.2

5

15

18

8.0

5.0

6

18

20

8.8

5.5

7

21

22

9.6

6.0

Bioelectrical Impedance
Intracellular and extracellular fluid values were determined using the Xitron 4200
Bio-Impedance Spectrum Analyzer. Subjects were placed in the supine position with
arms held comfortably abducted from their bodies by roughly 15 degrees and legs
separated comfortably. Electrodes were placed on the subjects’ left wrist and ankle.
Hydration
Hydration status was measured using the SPER Scientific Clinical Urine
refractometer. The device required 1-3 drops of a urine sample placed on a lens. The
device was then pointed at a light source and the level of refraction caused by the sample
was recorded.
21

Pulse Wave Analysis, Stroke Volume, and Ejection Time
Arterial compliance, stroke volume, and left ventricular ejection time were
measured using the HDI/PulseWave CR-2000TM Research Cardio Vascular Profiling
System. Subjects lay supine with their arms held comfortably abducted from their bodies
by roughly 15 degrees and legs separated comfortably. The wrist was supported while
measurements were being taken using the radial artery near the right hand wrist.

Pulse Wave Velocity
Pulse wave velocity was measured by the SphygmoCor® Pulse Wave Analyzer.
The subject had segmental measures taken with a segmometer (RealMet BCN,
Barcelona, Spain) from the right carotid to right radial artery, the carotid to the right
femoral artery, and also from the right femoral to the dorsalis pedis. Leads for ECG were
placed at the top and bottom of the sternum and at the bottom of the rib cage near the
midaxillary line.
Statistical Analysis
A 3-way analysis of variance (ANOVA) (CONDITION [Placebo vs. Supplement]
x TIME [varied depending on the variables] x CATEGORY [Male Athlete vs. Female
Athlete vs. Male Non-Athlete vs. Female Non-Athlete]) with repeated measures and
pairwise Bonferroni-adjusted estimated marginal means was used to see if significant
differences existed for analyzed variables. All repeated measures data was checked with
Mauchly’s Test of Sphericity. Where significant condition main effects were revealed,
the origin of effects was determined by paired t-tests. An alpha of 0.05 was used to
determine statistical significance and data was analyzed using SPSS 22.0 (IBM
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Corporation, New York, NY, USA) and Microsoft Excel 2013 for Windows (Redmond,
WA, USA).
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CHAPTER IV
RESULTS

The purpose of this study was to 1) examine the acute effects of the weight loss
aid, Shred Matrix, on hemodynamic responses (i.e., heart rate, blood pressure, stroke
volume, and ejection time), substrate utilization, endurance, arterial compliance, pulse
wave velocity, and body water distribution; 2) To investigate the differences between
athletes and non-athletes on the previously stated measures.
Subject Characteristics
The study tested 31 subjects, including 15 athletes (age= 22.6 (3.1)) and 16 nonathletes (age= 22.6 (3.9)) participants. Table 1 displays anthropometric measures of the
study population. Subjects were recruited from the University of Texas at Brownsville
campus, Texas Southmost College, and surrounding community.
Table 2. Anthropometric Data of Participants
Variables

Athlete Male
(n=7)

Athlete Female
(n=8)

Non-Athlete
Male (n=8)

Non-Athlete
Female (n=8)

Combined
Cohort (n=31)

Age (yr)

23.57 (±3.7)

21.75 (±2.0)

23.13 (±4.1)

22 (±3.9)

22.6 (3.5)

Height (cm)

174.29 (±4.7)

161.63 (±5.8)

179.25 (±6.7)

158.25 (±4.2)

168.16 (10.3)

Weight (kg)

73.86 (±9.0)

56.63 (±7.0)

88.38 (±9.6)

61.13 (±12.2)

69.87 (15.7)

VO2MAX
(ml/kg/min)

54.71 (±7.1)

52.45 (±8.6)

40.08 (±5.4)

36.15 (±3.8)

45.54 (10.1)

Values are reported as means (SD).

Body Water
Figures 1-2 show effects of exercise with and without supplement on athletes’ and
non-athletes’ extracellular fluid. Except for condition main effect, categories (male

athlete vs. male non-athlete vs. female athlete vs. female non-athlete) were statistically
similar (p>.05) for all effects and interactions and were reported together. Repeated
measures ANOVA found significant condition (p=.012) and time (p<.001) main effects.
Condition significance was determined by paired t-tests to originate in male non-athletes
at Post5 (p=.023) and Post30 (p=.009). For time, Pre was significantly different from
Post5 (p<.001) and Post30 (p<.001). Post5 was significantly different from Post30
(p<.001).
Figure 1. Athlete Extracellular Fluid.
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*T Significant time difference (p<.001). Values reported as mean ±SE.
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Figure 2. Non-Athlete Extracellular Fluid.
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*@ Significant condition difference for males at Post5 (p=.023) and Post30 (p=.009). *T significant
time difference (p<.001). Values reported as mean ±SE.

Figure 3 shows effects of exercise with and without supplement on athletes’
intracellular fluid. Repeated measures ANOVA detected a significant time (p<.001)
effect. For time, Pre was significantly different from Post30 (p<.001). Post5 was
significantly different from Post30 (p<.001).
Figure 3. Athlete Intracellular Fluid.
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Figure 4 shows effects of exercise with and without supplement on non-athlete
intracellular fluid. Repeated measures ANOVA showed significance for the time
(p<.001) main effect. For time, Pre was significantly different from Post30 (p<.001).
Post5 was significantly different from Post30 (p<.001).
Figure 4. Non-Athlete Intracellular Fluid.
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Figures 5-6 shows effects of exercise with and without supplement on athlete and
non-athlete urine specific gravity. Categories were statistically similar (p>.05) for all
effects and interactions; therefore, they were reported together. Repeated measures
ANOVA showed significant time (p<.001) differences. For time, Pre was significantly
different from Post5 (p=.009) and Post30 (p<.001). Post5 was significantly different
from Post30 (p<.001).
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Figure 5. Athlete Urine Specific Gravity.
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Figure 6. Non-Athlete Urine Specific Gravity.
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Hemodynamic Responses
Figures 7-8 show effects of exercise with and without supplement on athlete and
non-athlete systolic blood pressure. Except for condition main effect, categories were
statistically similar (p>.05) for all effects and interactions and were reported together.
Repeated measures ANOVA showed significant condition (p=.001) and time (p=<.001)
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main effects, and a trend for condition*time interaction (p=.067). For condition, paired ttests showed significance originated for male athletes at Post10 (p=.047) and Post20
(p=.01). For time, pre was significantly different from Post0 (p<.001) and Post40
(p=.038). Post0 was significantly different from Post10 (p<.001) and Post20 (p<.001).

SBP (mmHG)

Figure 7. Athlete Systolic Blood Pressure
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Figure 8. Non-Athlete Systolic Blood Pressure
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Figures 9-10 show effects of exercise with and without supplement on athlete and
non-athlete diastolic blood pressure. Except for condition main effect, categories were
statistically similar (p>.05) for all effects and interactions and were reported together.
Repeated measures ANOVA showed main effects for condition (p=.003) and time
(p=<.001), and a significant interaction for time*category (p=.042). For condition, paired
t-tests showed significance originated for male athletes at Post20 (p=.035) and for female
athletes at Post40 (p=.021). For time, Pre was significantly different from Post0
(p=.003). Post0 was significantly different from Post10 (p<.001), Post20 (p<.001), and
Post40 (p<.001).
Figure 9. Athlete Diastolic Blood Pressure
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Figure 10. Non-Athlete Diastolic Blood Pressure
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Figures 11-12 show effects of exercise with and without supplement on athlete
and non-athlete mean arterial pressure. Except for condition main effect, categories were
statistically similar (p>.05) for all effects and interactions and were reported together.
Repeated measures ANOVA showed significant main effects for condition (p=.001) and
time (p=<.001), and a trend for condition*category (p=.061) interaction. For condition,
paired t-tests showed significance originated in male athletes at Post20 (p=.046), female
athletes at Post10 (p=.037) Post20 (p=.048) and Post40 (p=.029), and in male nonathlete at Post10 (p=.014) and Post20 (p=.044). For time, Pre was significantly different
from Post0 (p<.001). Post0 was significantly different from Post10 (p<.001), Post20
(p<.001), and Post40 (p<.001). Post 10 was significantly different from Post20 (p=.043)
and Post40 (p=.024).
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Figure 11. Athlete Mean Arterial Pressure
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Figure 12. Non-Athlete Mean Arterial Pressure
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Figures 13-14 shows effects of exercise with and without supplement on athlete
and non-athlete pulse pressure. Except for condition main effect, categories were
statistically similar (p>.05) for all effects and interactions and were reported together.
Repeated measures ANOVA showed significant condition (p=.035) and time (p=<.001)
main effects. For condition, paired t-tests showed significance originated in male nonathletes at Post40 (p=.011). For time, Pre was significantly different from Post0
(p<.001). Post0 was significantly different from Post10 (p<.001), Post20 (p<.001), and
Post40 (p<.001).
Figure 13. Athlete Pulse Pressure
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Figure 14. Non-Athlete Pulse Pressure
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Figure 15 shows effects of exercise with and without supplement on athlete pulse
rate. Repeated measures ANOVA showed significant interactions for condition*time
(p=.001), condition*category (p=.009), time*category (p=.001), and significant
condition (p=.001) and time (p<.001) main effects. Both athlete groups had lower
exercise heart rates for each time point compared to their non-athlete counterparts. For
condition, paired t-tests showed significance originated in female athletes at Post10
(p=.038). For time, Pre was significantly different from Post0 (p<.001), Post10 (p<.001),
Post20 (p<.001), and Post40 (p<.001). Post0 was significantly different from Post10
(p<.001), Post20 (p<.001), and Post40 (p<.001). Post10 was significantly different from
Post20 (p<.001) and Post40 (p<.001). Post 20 was significantly different from Post40
(p<.001).
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Figure 15. Athlete Pulse Rate
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Figure 16 shows effects of exercise with and without supplement on non-athlete
pulse rate. Repeated measures ANOVA showed significant interactions for
condition*time (p=.001), condition*category (p=.009), time*category (p=.001), and
significant main effects for condition (p=.001) and time (p<.001). For condition, paired
t-tests showed significance originated in male non-athletes at Post0 (p=.014), Post10
(p<.001), Post20 (p=.004), and Post40 (p=.009). For time, Pre was significantly different
from Post0 (p<.001), Post10 (p<.001), Post20 (p<.001), and Post40 (p<.001). Post0 was
significantly different from Post10 (p<.001), Post20 (p<.001), and Post40 (p<.001).
Post10 was significantly different from Post20 (p<.001) and Post40 (p<.001). Post 20
was significantly different from Post40 (p<.001).
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Figure 16. Non-Athlete Pulse Rate
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Post40 (p=.009). *T significant time difference (p<.001). Values reported as mean ±SE.

Figures 17-18 show effects of exercise with and without supplement on athlete
and non-athlete cardiac ejection time. Categories were statistically similar (p>.05) for all
effects and interactions and were reported together. Repeated measures ANOVA showed
a significant time (p<.001) main effect. For time, Pre was significantly different from
Post0 (p<.001), Post10 (p<.001), Post20 (p<.001), and Post40 (p<.001). Post0 was
significantly different from Post10 (p<.001), Post20 (p<.001), and Post40 (p<.001).
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Figure 17. Athlete Cardiac Ejection Time
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Figure 18. Non-Athlete Cardiac Ejection Time
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Figures 19-20 show effects of exercise with and without supplement on athlete
and non-athlete stroke volume. Except for condition main effect, categories were
statistically similar (p>.05) for all effects and interactions and are reported together.
Repeated measures ANOVA showed a significant condition*time interaction (p=.016),
condition main effect (p=.033), and time main effect (p<.001). For condition, paired t37

tests showed significance originated in non-athlete females at Post0 (p=.012). For time,
Pre was significantly different from Post0 (p<.001), Post10 (p<.001), Post20 (p<.001),
and Post40 (p<.001). Post0 was significantly different from Post10 (p<.001), Post20
(p<.001), and Post40 (p<.001). Post10 was significantly different from Post20 (p<.001)
and Post40 (p<.001). Post 20 was significantly different from Post40 (p<.001).
Figure 19. Athlete Stroke Volume
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Figure 20. Non-Athlete Stroke Volume
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Figures 21-22 show effects of exercise with and without supplement on athlete
and non-athlete stroke volume index. Except for condition main effect, categories were
statistically similar (p>.05) for all effects and interactions and are reported together.
Repeated measures ANOVA showed a significant condition*time (p=.001) interaction,
and condition (p=.007) and time (p<.001) main effects. For condition, paired t-tests
showed significance originated in non-athlete females at Post0 (p=.013). For time, Pre
was significantly different from Post0 (p<.001), Post10 (p<.001), Post20 (p<.001), and
Post40 (p<.001). Post0 was significantly different from Post10 (p<.001), Post20
(p<.001), and Post40 (p<.001). Post10 was significantly different from Post20 (p<.001)
and Post40 (p<.001). Post 20 was significantly different from Post40 (p=001).
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Figure 21. Athlete Stroke Volume Index
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Figure 22. Non-Athlete Stroke Volume Index
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Figures 23-24 shows effects of exercise with and without supplement on athlete
and non-athlete cardiac output. Categories were statistically similar (p>.05) for all effects
and interactions and are reported together. Repeated measures ANOVA showed a
significant main effect for time (p<.001) and a trend for condition*time (p=.081)
interaction. For time, Pre was significantly different from Post10 (p<.001), Post20
40

(p<.001), and Post40 (p=.001). Post0 was significantly different from Post10 (p<.001)
and Post20 (p=.003). Post 20 was significantly different from Post40 (p=.006).
Figure 23. Athlete Cardiac Output
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Figure 24. Non-Athlete Cardiac Output
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Figures 25-26 show effects of exercise with and without supplement on athlete
and non-athlete vascular resistance. Except for condition main effect, categories were
statistically similar (p>.05) for all effects and interactions and were reported together.
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Repeated measures ANOVA showed significant condition (p=.05) and time (p<.001)
main effects. For condition, paired t-tests showed significance originated in male athletes
at Post 20 (p=.017) and female athletes at Post20 (p=.018) and Post40 (p=.032). For
time, Pre was significantly different from Post10 (p<.001), Post20 (p<.001), and Post40
(p<.001). Post0 was significantly different from Post10 (p=.008) and Post20 (p=.035).
Figure 25. Athlete Vascular Resistance
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Figure 26. Non-Athlete Vascular Resistance
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Figures 27-28 show effects of exercise with and without supplement on athlete
and non-athlete vascular impedance. Categories were statistically similar (p>.05) for all
effects and interactions and were reported together. Repeated measures ANOVA showed
a significant time (p<.001) main effect and a trend for condition (p=.076) main effect.
For time, Pre was significantly different from Post10 (p<.001), Post20 (p<.001), and
Post40 (p=.014). Post0 was significantly different from Post10 (p<.001) and Post20
(p=.003). Post10 was significantly different from Post40 (p=.042).
Figure 27. Athlete Vascular Impedance
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Figure 28. Non-Athlete Vascular Impedance
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Arterial Compliance
Figures 29-30 show effects of exercise with and without supplement on
athlete and non-athlete pulse wave velocity from the carotid to radial artery. Except for
condition main effect, categories were statistically similar (p>.05) for all effects and
interactions and were reported together. Repeated measures ANOVA showed significant
condition (p=.01) and time (p=<.001) main effects. For condition, paired t-test analysis
showed significance originated in female athletes at Post15 (p=.032) and Post25
(p=.019). For time, Pre was significantly different from Post10 (p=.004), Post20
(p=.008), and Post40 (p=.017).
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Figure 29. Athlete Pulse Wave Velocity- Carotid to Radial
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Figure 30. Non-Athlete Pulse Wave Velocity- Carotid to Radial
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Figure 31 shows effects of exercise with and without supplement on athlete pulse
wave velocity from the carotid to femoral segment. Repeated measures ANOVA showed
a significant condition*time (p=.01) and condition*category (p=.038) interaction. There
was also a significant condition (p=.003) main effect. Paired t-test analysis showed
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condition significance originated in male athletes at Post15 (p=.027) and Post35 (p=.005)
and in female athletes at Post35 (p=.016).
Figure 31. Athlete Pulse Wave Velocity- Carotid to Femoral
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Figure 32 shows effects of exercise with and without supplement on non-athlete
pulse wave velocity from the carotid to femoral segment. Repeated measures ANOVA
showed a significant condition*time (p=.01) and condition*category (p=.038)
interaction. There was also a significant main effect for condition (p=.003). Paired t-test
analysis showed condition significance originated in female non-athletes at Post15
(p=.016) and Post25 (p=.03). There was no significant condition effect found for male
non-athletes.
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Figure 32. Non-Athlete Pulse Wave Velocity- Carotid-Femoral
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Figures 33-34 show effects of exercise with and without supplement on athlete
and non-athlete pulse wave velocity from the femoral to distal segment. Categories were
statistically similar (p>.05) for all effects and interactions and were reported together.
Repeated measures ANOVA showed a significant condition*time (p=.018) interaction.
There was also a significant time (p=<.001) main effect. For time, Pre was significantly
different from Post0 (p<.001), Post10 (p=.001), and Post20 (p=.006). Post0 was
significantly different from Post20 (p=.009), and Post40 (p=.046).
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Figure 33. Athlete Pulse Wave Velocity- Femoral to Distal
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Figure 34. Non-Athlete Pulse Wave Velocity- Femoral to Distal
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Figures 35-36 show effects of exercise with and without supplement on athlete
and non-athlete large arterial elasticity. Except for condition main effect, categories were
statistically similar (p>.05) for all effects and interactions and are reported together.
Repeated measures ANOVA showed significant condition (p=.003) and time (p=<.001)
main effects. There was also a trend for condition*time (p=.096) interaction. For
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condition, paired t-test analysis showed significance originated in male athletes at Post20
(p=.05) and in female athletes at Post10 (p=.012). For time, Pre was significantly
different from Post0 (p=.001). Post0 was significantly different from Post10 (p<.001),
Post20 (p<.001), and Post40 (p=.001).
Figure 35. Athlete Large Arterial Elasticity
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Figure 36. Non-Athlete Large Arterial Elasticity
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Substrate Utilization
Figures 37-38 show effects of exercise with and without supplement on athlete
and non-athlete respiratory exchange ratio. Except for condition main effect, categories
were statistically similar (p>.05) for all effects and interactions and are reported together.
Repeated measures ANOVA showed significant condition (p=.034) time (p=.001) main
effects through 15 minutes of treadmill running. VO 2 and heart for the same time length
was not statistically significant for condition. For condition, paired t-test analysis showed
significance originated in male non-athletes at min3 (p=.003), min6 (p=.03), min9
(p=.025), and min12 (p=.025). For time, Post0 was significantly different from Post10
(p<.001), Post20 (p=.001), and Post40 (p=.001).
Figure 37. Athlete Respiratory Exchange Ratio
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Figure 38. Non-Athlete Respiratory Exchange Ratio
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Endurance
Figure 39 shows athlete running times with and without supplement to volitional
fatigue. Male athletes ran 36.47 (±15.83) minutes on the placebo and 41.28 (±20.99)
minutes on the supplement. Female athletes ran 21.71 (±2.95) minutes on the placebo
and 22.1 minutes (±2.49) on the supplement.
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Figure 39. Athlete Running Time
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Figure 40 shows non-athlete running times of exercise with and without
supplement to volitional fatigue. There was a significant difference for running time to
volitional fatigue for female non-athletes (p=.033). Male non-athletes ran 29.27 (±4.76)
on the placebo and 28 (±4.01) minutes on the supplement. Female non-athletes ran 23.64
(±2.94) minutes on the placebo and 25.31 (±2.67) minutes on the supplement.
Figure 40. Non-Athlete Running Time
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CHAPTER V
DISCUSSION

The purpose of this study was to 1) examine the acute effects of the weight loss
aid, Shred Matrix, on hemodynamic responses (i.e., heart rate, blood pressure, stroke
volume, and ejection time), substrate utilization, endurance, arterial compliance, pulse
wave velocity, and body water distribution; 2) To investigate the differences between
athletes and non-athletes on the previously stated measures.
Body Water
There were no significant differences between conditions for the combined cohort
of for any individual group for urine specific gravity. Based on these results, it can be
assumed that hydration did not play a role for hemodynamic responses or performance
for running time to exhaustion.
Extracellular fluid differences for the supplement condition in male non-athletes
were also not a barrier to performance. While post exercise ECF levels were lower in the
supplement condition, they did not drop below pre-exercise values. Intracellular fluids for
the same group and condition also did not drop below the pre-exercise levels, indicating
that there was no drop in total body water from sweating that would cause a decrease in
performance in relation to the placebo condition (Case et al., 2000).
Though the supplement contains the diuretics dandelion root and uva ursi leaf, an
acute dosage did not appear to have any measurable effect on hydration or total body
water, though the male non-athletes showed lower ECF during the supplement condition.

Had the supplement caused an acute effect through diuresis, there should have been a
lowering of blood pressure from lower systemic blood volume, however none was found.
Caffeine has also been found in some instances to be a mild diuretic. However,
the literature suggests that the diuresis is similar to that caused by drinking plain water.
The reported effects indicate there is no evidence for enough water loss from caffeine to
cause any decreases in performance (Armstrong, 2002).
Hemodynamic Responses
There were significant differences in blood pressures between conditions postexercise. The condition*time interaction showed that the increase in systolic blood
pressure was directly related to the taking of the supplement. This finding is similar to
another study that observed the effects of caffeine supplementation on exercise,
consisting of submaximal, followed by maximal cycling. The authors speculated that the
increase in systolic and diastolic pressure was caused by increases in vascular resistance
from peripheral vasoconstriction. The vasoconstriction was caused by caffeine’s
antagonist effects on the vasodilator, adenosine, and epinephrine’s activation of alpha-1
receptors in the smooth muscle of the arteries (Pincomb et al., 1985; Sung et al., 1990).
Evidence that caffeine is the cause for increases in central pressures in this study is
furthered supported by significant increases in vascular resistance, diastolic blood
pressure, mean arterial pressure, pulse pressure, pulse rate and decreased stroke volume.
Another study evaluating the effects of a thermogenic supplement during and
after exercise found increases in heart rate, systolic blood pressure, and diastolic blood
pressure. Subjects (13 women, 15 men) ingested a supplement containing caffeine,
capsaicin, and other ingredients, rested for approximately 50 minutes, and then walked on
a treadmill at a self-selected pace for an hour. Though the study did not have subjects
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exercise at vigorous intensity, heart was significantly elevated above resting values,
allowing similar effects to occur post-exercise compared to the current study (Ryan et al.,
2009).
Condition*time interactions were observed for pulse rate and stroke volume, but
there was no significant difference in total cardiac output between conditions. Higher
pulse rates for the supplement condition led to a decreased stroke volume from shorter
duration left ventricular filling. The placebo condition showed slower heart rates with
larger stroke volumes.
It appears that garlic had no effect on blood pressure in this study. This was either
due to an ineffectively low dosage, interference from caffeine, subject sampling from a
non-hypertensive population, or varied combinations of the three. For athletes, results of
the current study coincide with the study performed by Morris et al. (2013) that found no
significant differences in blood pressures in athletes cycling under hypoxic conditions.
The other study mentioned previously, by Ried et al. (2013), concerning garlic, showed
significant decreases in blood pressure. However, the subjects in the study were
considered hypertensive. In the current study, all subjects were normotensive or
prehypertensive.
Arterial Compliance
Both pulse wave velocity and arterial elasticity measures showed an increase in
stiffness of the large arteries above the placebo condition. This evidence is supported by
the previously mentioned article by Mahmud and Feely (Mahmud & Feely, 2001). While
their study did not observe subjects during or post-exercise, negative changes in pulse
wave velocity at rest caused by caffeine are a plausible indication that the same effects
can be observed from exercise.
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Another study performed on young and healthy males and females also showed
increases in arterial stiffness with increases in pulse wave velocity after ingestion of
caffeine. In their study, 8 males and eight females ingested 80mg of caffeinated or
decaffeinated coffee on separate visits. Subjects were then monitored at rest and
measurements were taken every thirty minutes for two hours. Diastolic blood pressure
was also found to be higher in the caffeine condition (Karatzis et al., 2005).
An acute dosage of turmeric from the supplement did not have an effect on postexercise arterial stiffness outcomes. There was either not enough turmeric in the dosage
to see a response, caffeine masked any benefits derived, or it may take a longitudinal
study to observe the same positive effects seen from the study by Akazawa et al (2013).
Substrate Utilization
The supplement caused a significantly higher respiratory exchange ratio through
the first 15 minutes of exercise, especially in male non-athletes. Due to loss of statistical
power for groups after 15 minutes, no further time points were included. The higher RER
indicates that a higher rate of glycolysis was being used to meet energy demands (Powers
& Howley, 2009, pp. 59-60).
Eleutherococcus senticosus (ES) has been previously shown to increase
endurance in recreationally trained men participating in an 8 week training study (Kuo,
2010). The current study containing ES contradicts those findings. However, the
previously mentioned study was a training study, not acute, they performed cycling
exercise at 75% VO 2, and the supplement did not include other ingredients that may
interfere.
Other ingredients that affect blood glucose, including capsaicin, gymnema
sylvestre, and banaba extract were mentioned in the literature review. These ingredients
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have been previously found to affect how carbohydrate is absorbed and the effects on
insulin response (Al-Romaiyan et al., 2010; Dömötör et al., 2006; Fernandez-Mejia,
2005; Kang et al., 2010; Kurian et al., 2014; Tsuchibe et al., 2006; Weerapan
Khovidhunkit, 2009). Because this study required that subjects be fasted for participation,
there was no measurable effect these ingredients had on their intended purposes.
Endurance
Overall, there were no significant differences between the supplement and
placebo conditions. Female non-athletes alone showed significantly longer time to
volitional fatigue. Graham and Spriet (1995) have previously shown that various dosages
of caffeine affect well-trained endurance athletes differently depending on the dosage. In
their study, subjects ingested a placebo, 3 mg/kg, 6 mg/kg, or 9 mg/kg of caffeine. After a
period of rest, subjects ran at 85% of their VO 2MAX until volitional fatigue. The times to
exhaustion varied between groups, but only the 3 and 6 mg/kg trial lasted significantly
longer. A notable finding from the study is that only the 9 mg/kg trial had significant
increases in plasma FFA and glycerol with the greatest effect on epinephrine. This should
have correlated to higher FFA use and glycogen sparing, but time to exhaustion indicated
that it was not the most effective condition (Graham & Spriet, 1995).
In the current study, the dosage of supplement was uniform for all subjects,
meaning caffeine ingestion was relatively different for individuals and between groups.
The supplement in the current study contained 217.5 mg of caffeine per serving
according to its label. This equated to male athletes receiving an average of 2.94 mg/kg,
female athletes 3.84 mg/kg, male non-athletes 2.46 mg/kg, and female non-athletes
ingested 3.56 mg/kg of caffeine. Dosages appear to be similar for all groups in the current
study. However, it has also been shown that tolerance to habitual caffeine use can affect
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treadmill running time to exhaustion at a similar intensity of 75% V02 max (Fisher,
McMurray, Berry, Mar, & Forsythe, 1986). The members of the female non-athlete group
might consume less caffeine daily compared to the other groups, showing less tolerance,
and resulting in an increased time to exhaustion. This is a possible explanation as to why
the group was the only one to last significantly longer.

CONCLUSION

The purpose of this study was to 1) examine the acute effects of the weight loss
aid, Shred Matrix, on hemodynamic responses (i.e., heart rate, blood pressure, stroke
volume, and ejection time), substrate utilization, endurance, arterial compliance, pulse
wave velocity, and body water distribution; 2) To investigate the differences between
athletes and non-athletes on the previously stated measures. This study asked: Was there
a significant increase in fat metabolism when the weight loss aid, Shred Matrix, is
consumed prior to exercise? What were the changes in exercise HR, exercise diastolic
and systolic BP? Was there a significant effect on stroke volume? Was there a significant
effect on ejection time? Was there an increase in exercise endurance? Was there a change
in arterial compliance? Was there a significant effect on pulse wave velocity? Was there a
change in intracellular and/or extracellular body water?

Research Hypothesis 1. There was a greater amount of fat metabolism with Shred
matrix during exercise.
The results of the present study did not support this hypothesis. It was
hypothesized that caffeine would mobilize more fatty acids from adipose tissue and spare
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glycogen stores. However, RER values, especially in male non-athletes, indicated an
increased use of carbohydrate during the first 15 minutes of treadmill running at 80% of
VO 2MAX.

Research Hypothesis 2. Shred Matrix resulted in lower increases in HR, diastolic
and systolic blood pressures at different time points compared to placebo.
The results of the present study did not support this hypothesis. Based on a study
by McClaran and Wetter (2007), we hypothesized that caffeine would cause a lower heart
rate response during sub-maximal exercise. However, Shred Matrix resulted in no
significant difference during exercise for heart rate.
Due to garlic’s vasodilation capabilities reported in a previously mentioned study,
we hypothesized that peripheral vascular resistance would be lower with the supplement.
Lower resistance would bring about lower blood pressures. Pulse rate, SBP, and DBP
were all higher post-exercise for Shred Matrix compared to the placebo at different time
points.

Research Hypothesis 3. There was a significant increase in stroke volume.
The results of the present study did not support this hypothesis. It was
hypothesized that the expected lower heart rate would leave more time for left ventricular
filling and result in increased stroke during systole with the supplement condition.
However, stroke volume was lower post-exercise compared to the placebo.
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Research Hypothesis 4. There was an increase in cardiac ejection time.
The evidence gathered in the present study did not support the hypothesis. With
the expected lower heart and longer stroke volume, it was expected that cardiac ejection
time would last longer with the supplement. However, the present study did not find any
significant changes in CET.

Research Hypothesis 5. Shred Matrix resulted in increased time to exhaustion.
The results of the present study did not support this hypothesis. The hypothesized
increase in fat metabolism and subsequent glycogen sparing would potentially allow
subjects to continue running for a longer duration. Overall mean time to exhaustion was
higher for Shred Matrix, but was only significant for female non-athletes.

Research Hypothesis 6. There was an increase in large and small arterial elasticity.
The results of the present study did not support this hypothesis. With the
hypothesized decrease in vascular resistance, there would be a decrease in central and
peripheral pressures, allowing increased arterial compliance. However, shred matrix
caused decreases in large arterial elasticity and no changes for small arterial elasticity
compared to the placebo.

Research Hypothesis 7. There was a decrease in pulse wave velocity.
The results of the present study did not support this hypothesis. Hypothesized
decreases in vascular resistance and increased arterial elasticity would also cause lower
wave reflections, placing less strain on the heart, and result in decreased pulse wave
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velocity (Nichols et al., 2008). Shred matrix caused in increase in pulse wave velocity
compared to the placebo.

Research Hypothesis 8. There was an increase in extracellular water.
The results of the present study did not support this hypothesis. It was
hypothesized that with the presence of potassium aspartate, there was a possibility of a
fluid shift from extracellular to intracellular fluid. Non-athlete males were the only group
to undergo significant changes in extracellular fluid. The ECF for male non-athletes was
lower than the placebo.
This study observed acute negative effects for multiple variables. These included
higher blood pressures, lower arterial elasticity, and increased pulse wave velocity postexercise during days where Shred Matrix was ingested compared to a placebo. These
measures indicate an increased risk for a possible cardiovascular event (Mahmud &
Feely, 2001; Papaioannou, Karatzi, Karatzis, Papamichael, & Lekakis, 2005).
Simply because a weight loss supplement is marketed for athletes does not mean
it is recommended to take. The term “athlete” encompasses a vast array of sports
requiring different energy demands. In the present study where higher intensities of
aerobic running were used, athletes did not statistically perform better while on the
supplement. Furthermore, if chronic use does cause a measurable diuretic effect, the loss
of water could have a negative effect on athletic performance and can even become a
safety concern (Case et al., 2000).
Both athletes and non-athletes should educate themselves before purchasing
supplements to determine both effectiveness and potential harmful effects. Also,
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conversing with a physician may help determine if a supplement is safe or if a preexisting
condition exists that makes taking a supplement contraindicated.
To ameliorate caffeine’s negative effects on hemodynamics and arterial
compliance, supplement manufacturers should look into reformulating products in an
effort to offset those negative effects. For example, the current supplement could be
modified to use more garlic and turmeric in relation to caffeine to improve vasodilation
and arterial elasticity.
It is recommended that future studies involving weight loss supplements
containing ingredients affecting carbohydrate absorption incorporate carbohydrate
feeding so that insulin effects can be measured in addition to performance. Long-term
studies can also be conducted testing products containing diuretics and their effects on
both athletic performance and cardiovascular health.
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Appendix A. List of Abbreviations
ANOVA -Analysis of Variance
CET

-Cardiac Ejection Time

CNS

-Central Nervous System

CO

-Cardiac Output

DBP

-Diastolic Blood Pressure

ECF

-Extracellular Fluid

ES

-Eleutherococcus senticosus

FDA

-Food and Drug Administration

FFA

-Free Fatty Acid

HR

-Heart Rate

ICF

-Intracellular Fluid

LAE

-Large Arterial Elasticity

MAP

-Mean Arterial Pressure

PAR-Q

-Physical Activity Readiness Questionnaire

PP

-Pulse Pressure

PPAR

-Peroxisome Proliferator-Activated Receptor

PR

-Pulse Rate

PWV

-Pulse Wave Velocity

RER

-Respiratory Exchange Ration

SAE

-Small Arterial Elasticity

SBP

-Systolic Blood Pressure

SV

-Stroke Volume

SVI

-Stroke Volume Index

USG

-Urine Specific Gravity

VI

-Vascular Impedance

VR

-Vascular Resistance
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